Evidence map›Paper›PMID 29648920›Full record

ArticlemAbs

Functional domain analysis of SOX18 transcription factor using a single-chain variable fragment-based approach.

Frank R Fontaine, Stephen Goodall, Jeremy W Prokop, Christopher B Howard, Mehdi Moustaqil, Sumukh Kumble, Daniel T Rasicci, Geoffrey W Osborne, Yann Gambin, Emma Sierecki and 4 more

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Frank R Fontainea Institute for Molecular Bioscience, The University of Queensland , Brisbane , Australia.ORCID 0000-0002-3133-8093
Stephen Goodallb Australian Institute for Bioengineering and Nanotechnology, The University of Queensland , QLD , Australia.
Jeremy W Prokopc HudsonAlpha Institute for Biotechnology , Huntsville AL , USA.
Christopher B Howardb Australian Institute for Bioengineering and Nanotechnology, The University of Queensland , QLD , Australia.
Mehdi Moustaqilf Single Molecule Science, Lowy Cancer Research Centre, The University of New South Wales , Sydney , NSW , Australia.
Sumukh Kumbleb Australian Institute for Bioengineering and Nanotechnology, The University of Queensland , QLD , Australia.
Daniel T Rasiccic HudsonAlpha Institute for Biotechnology , Huntsville AL , USA.
Geoffrey W Osbornee ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland , St Lucia , QLD , Australia.
Yann Gambinf Single Molecule Science, Lowy Cancer Research Centre, The University of New South Wales , Sydney , NSW , Australia.
Emma Siereckif Single Molecule Science, Lowy Cancer Research Centre, The University of New South Wales , Sydney , NSW , Australia.
Martina L Jonese ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland , St Lucia , QLD , Australia.
Johannes Zuegga Institute for Molecular Bioscience, The University of Queensland , Brisbane , Australia.
Stephen Mahlerb Australian Institute for Bioengineering and Nanotechnology, The University of Queensland , QLD , Australia.
Mathias Francoisa Institute for Molecular Bioscience, The University of Queensland , Brisbane , Australia.
The University of Queensland · AUUNSW Sydney · AUHudsonAlpha Institute for Biotechnology · US

Funding

Using a Sequence-to-Structure-to-Function Approach to Functionally Characterize Protein Coding Missense Mutations in the Human and Rat GenomesK01ES025435 · NIEHS · MICHIGAN STATE UNIVERSITY · PI PROKOP, JEREMY WILLIAM · 2014 to 2018
$489k
NIEHS NIH HHS K01 ES025435
6 · The paper itself

Abstract

Antibodies are routinely used to study the activity of transcription factors, using various in vitro and in vivo approaches such as electrophoretic mobility shift assay, enzyme-linked immunosorbent assay, genome-wide method analysis coupled with next generation sequencing, or mass spectrometry. More recently, a new application for antibodies has emerged as crystallisation scaffolds for difficult to crystallise proteins, such as transcription factors. Only in a few rare cases, antibodies have been used to modulate the activity of transcription factors, and there is a real gap in our knowledge on how to efficiently design antibodies to interfere with transcription. The molecular function of transcription factors is underpinned by complex networks of protein-protein interaction and in theory, setting aside intra-cellular delivery challenges, developing antibody-based approaches to modulate transcription factor activity appears a viable option. Here, we demonstrate that antibodies or an antibody single-chain variable region fragments are powerful molecular tools to unravel complex protein-DNA and protein-protein binding mechanisms. In this study, we focus on the molecular mode of action of the transcription factor SOX18, a key modulator of endothelial cell fate during development, as well as an attractive target in certain pathophysiological conditions such as solid cancer metastasis. The engineered antibody we designed inhibits SOX18 transcriptional activity, by interfering specifically with an 8-amino-acid motif in the C-terminal region directly adjacent to α-Helix 3 of SOX18 HMG domain, thereby disrupting protein-protein interaction. This new approach establishes a framework to guide the study of transcription factors interactomes using antibodies as molecular handles.

Indexed as

Single-Chain AntibodiesHumansSOXF Transcription FactorsSingle-Chain AntibodiesSOX18 protein, humanSOXF Transcription Factorsantibodyprotein-protein interactionscFvSOX18 transcription factortranscriptional activation.

Identifiers

PMID29648920
PMCPMC5972640
OpenAlexW2797175072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.